DBVT News and Press, DBV Technologies S.A. From 02/14/22

Montrouge, France, February 14, 2022 DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conferenc e DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, ...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market: NYSE Euronext Paris ISIN C...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ...

Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Shares of DBV Technologies (DBVT +13.3%) have recouped some of their losses from yesterday after the company announced a new late-stage trial for its Viaskin peanut allergy patch. The trial will evaluate a modified patch that is 50% larger than a previous version. Kempen analyst Alex Cogut to...

BiondVax Pharmaceuticals (NASDAQ:BVXV) +55% signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany. BioRestorative Therapi...

Gainers: Reliance Global Group (NASDAQ:RELI) +89%. Biofrontera  (NASDAQ:BFRI) +49%. IsoPlexis Corporation (NASDAQ:ISO) +37%. Chemomab Therapeutics  (NASDAQ:CMMB) +29%. iSpecimen  (NASDAQ:ISPC) +28%. Aldeyra Therapeutics (NASDAQ:ALDX) -51%. DBV Technologies&#...

Gainers: Reliance Global Group (NASDAQ:RELI) +82%. Biofrontera (NASDAQ:BFRI) +49%. Jaguar Health (NASDAQ:JAGX) +43%. IsoPlexis (NASDAQ:ISO) +31%. Aridis Pharmaceuticals (NASDAQ:ARDS) +28%. Petros Pharmaceuticals (NASDAQ:PTPI) +30%. Eqonex (NASDAQ:EQOS) +26%. Quantum-Si incorporated (NASDAQ:QS...

Shares of DBV Technologies (NASDAQ: DBVT) , a clinical-stage biopharmaceutical company, took a sharp turn for the worse today. Investors reacting to disappointing news about the development of Viaskin Peanut, its treatment for those with peanut allergies, pushed the stock 37.8% lowe...

DBV Technologies (DBVT -41.1%) ADRs have lost sharply after the company announced its plans to begin a new Phase 3 pivotal trial for the modified Viaskin Peanut patch. The study for the intended patient population will be designed to evaluate the modified Viaskin Peanut (mVP) patch, which is ...